Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Addy C, Rothenberg P, Li S, Majumdar A, Agrawal N, Li H, Zhong L, Yuan J, Maes A, Dunbar S, Cote J, Rosko K, Van Dyck K, De Lepeleire I, de Hoon J, Van Hecken A, Depré M, Knops A, Gottesdiener K, Stoch A, Wagner J.
Addy C, et al. Among authors: gottesdiener k.
J Clin Pharmacol. 2008 Jun;48(6):734-44. doi: 10.1177/0091270008317591.
J Clin Pharmacol. 2008.
PMID: 18508950
Clinical Trial.